| Description |
1 online resource (312 p.) |
| Contents |
Cover -- Title -- Copyright -- Contents -- Acronyms/Abbreviations -- Introduction -- Rationale -- Scope of Document -- Overview of the Development Process -- Rating the Strengths of Guideline Statements and Supporting Research Evidence -- Proper Use of Guidelines -- Guideline Statement Summary -- Guideline Statements and Implementation -- Assessment and Determination of Treatment Plan -- Statement 1: Assessment of Possible Schizophrenia -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement |
|
Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 2: Use of Quantitative Measures -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 3: Evidence-Based Treatment Planning -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations |
|
Quality Measurement Considerations -- Pharmacotherapy -- Statement 4: Antipsychotic Medications -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 5: Continuing Medications -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 6: Continuing the Same Medications |
|
Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 7: Clozapine in Treatment-Resistant Schizophrenia -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 8: Clozapine in Suicide Risk -- Implementation |
|
Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 9: Clozapine in Aggressive Behavior -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 10: Long-Acting Injectable Antipsychotic Medications -- Implementation |
| Summary |
The guideline focuses specifically on evidence-based pharmacological and nonpharmacological treatments for schizophrenia and includes statements related to assessment and treatment planning, which are an integral part of patient-centered care. The guideline provides direction on implementing these recommendations into clinical practice, with the goal of improving the quality of care and treatment outcomes for patients with schizophrenia |
| Notes |
Description based upon print version of record |
|
Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement |
| Subject |
Schizophrenia -- Treatment
|
|
Schizophrenia -- therapy
|
|
Schizophrenia -- Treatment
|
| Form |
Electronic book
|
| ISBN |
9780890424742 |
|
0890424748 |
|
